The forecasted data for anxiolytic medicine sales in Germany from 2024 to 2028 indicates a steady state at 0.1% of total sales annually. There is no expected growth or decline in sales over these five years. For context, sales in 2023 were at a similar level, showing a stagnation in market growth with no significant year-on-year variation and a calculated CAGR of 0%, indicating a consistent trend without growth.

Future trends to watch for:

The impact of regulatory changes in the healthcare sector which could influence anxiolytic prescriptions.
Potential shifts in public perception of mental health treatments and an increased preference for non-pharmaceutical alternatives.
Evolving competitive landscape and market entry of new or generic medications affecting sales dynamics.